Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 pharmacokinetics study of ASTX030 in myelodysplastic syndrome
jRCT2021200025Phase 1Recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cedazuridine + azacitidine in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (3 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Started Nov 2020; status: recruiting.
02
Drugs
cedazuridine + azacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on jRCT2021200025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021200025.